Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Crinetics Pharmaceuticals ( (CRNX) ) has issued an update.
Crinetics Pharmaceuticals announced positive topline results from its Phase 2 study of atumelnant, an ACTH receptor antagonist candidate for treating congenital adrenal hyperplasia (CAH). The study showed significant reductions in key biomarkers and improvements in clinical signs, supporting the initiation of a Phase 3 trial. With atumelnant being well-tolerated and showing no severe adverse events, Crinetics aims to advance its development, furthering its strategy to become a leading global endocrine company.
More about Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company dedicated to discovering, developing, and commercializing novel therapeutics for endocrine diseases and endocrine-related tumors. Their drug candidates, including paltusotine and atumelnant, are orally delivered, small molecule entities discovered in-house, focusing on conditions such as acromegaly, Cushing’s syndrome, and congenital adrenal hyperplasia.
YTD Price Performance: -5.92%
Average Trading Volume: 719,219
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $4.5B
For detailed information about CRNX stock, go to TipRanks’ Stock Analysis page.
